A Trump administration appointee has delayed publication of a Centers for Disease Control and Prevention report that reportedly shows clear benefits linked to the Covid vaccine, prompting alarm among those who say the administration may be working behind the scenes to undermine vaccines.
According to reporting from the Washington Post, CDC scientists found that the Covid vaccine reduced the likelihood of emergency room visits and hospitalizations for healthy adults last winter by about half. The report has not been released publicly after being held up by the acting CDC director, Jay Bhattacharya.
The delay has drawn attention because the study is described as showing a significant reduction in severe illness among healthy adults. Instead of moving ahead with publication, Bhattacharya reportedly raised concerns about the research methodology, leading to the pause.
The episode has added to worries about the direction of federal public health messaging under the Trump administration. Critics argue that withholding a report with favorable vaccine findings could fuel confusion at a time when vaccination remains an important public health tool.
The CDC study appears to focus on last winter’s outcomes and compares the risks of emergency room treatment and hospitalization for vaccinated adults with those who were not vaccinated. The reported result — roughly a 50% reduction in those outcomes — is likely to be seen as a significant finding in the continuing debate over Covid vaccine effectiveness.
Bhattacharya’s role in delaying the report has also intensified scrutiny of how the CDC handles scientific publications under political leadership. The concern is not only about the report itself, but also about whether decisions over publication are being shaped by politics rather than public health evidence.
For now, the report remains unpublished while its methodology is reviewed. The delay has become a focal point for questions about transparency, vaccine messaging, and the balance between scientific review and administrative control at one of the country’s top public health agencies.
